Life sciences leaders cite similar distress drivers and expect IRA-linked pricing pressure; global pricing dynamics, competitive intensity, and payer/PBM leverage threaten pricing power while AI ROI ...

Pathogenic variants were present in 0.5% (GMC) to 0.9% (UKBB), with MITF E318K accounting for most carriers and reaching 0.8% in UKBB. Enrichment exceeded a 2.5% testing threshold in high-risk ...

Meena Bansal, MD, discusses the evolving MASH pipeline and why precision phenotyping, biomarkers, and cardiovascular outcomes ...

Fragmented subspecialty care and underbuilt survivorship pathways risk overwhelming primary care as the survivor population ...

Fee-for-service beneficiaries had higher BGP use than Medicare Advantage (25.8% vs 24.6%; AOR 1.08), indicating payer ...

Effective compliance now spans transaction eligibility, OPAIS synchronization, Medicaid exclusion validation, cost-report ...

Full results from the pivotal B-Well 1 and B-Well 2 phase 3 trials confirm that bepirovirsen delivers statistically significant functional cure rates in chronic hepatitis B. Bepirovirsen (GSK/Ionis ...

International benchmarking across coverage/access, affordability, equity, and delivery places the US as the highest spender, far exceeding Switzerland ($7,927 per capita), without commensurate outcome ...

Age-stratified outcomes favored adolescents (48.6% SALT ≤20) versus adults (21.9%), plausibly related to shorter disease duration, shorter current episode, and greater follicular regenerative capacity ...

Kerry Rogers, MD, breaks down the clinical and lifestyle factors that drive frontline treatment selection between BTK ...

Weekly AHB-137 300 mg for 16 weeks achieved HBV DNA <10 IU/mL in 100% and complete response in 68% at end of treatment without concomitant nucleos(t)ide analogues. Baseline HBsAg stratified outcomes, ...

Outpatient visits for serious mental illness rose about 3.1%–3.5% after expirations, without significant changes in overall ...